Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions.
作者信息
Sulkowski Mark, Wyles David
机构信息
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Denver Health Medical Center, Denver, Colorado, USA.
出版信息
Clin Infect Dis. 2021 Nov 2;73(9):e3296-e3299. doi: 10.1093/cid/ciaa1329.
Abstract
摘要
相似文献
1
Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions.
Clin Infect Dis. 2021 Nov 2;73(9):e3296-e3299. doi: 10.1093/cid/ciaa1329.
2
Direct acting antivirals failure: cause and retreatment options.
Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1245-1250. doi: 10.1080/17474124.2018.1541237. Epub 2018 Oct 31.
3
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.
4
Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
Hepatology. 2023 Aug 1;78(2):607-620. doi: 10.1097/HEP.0000000000000379. Epub 2023 Apr 1.
5
Editorial: Retreatment of direct-acting antiviral failures with the current first-line regimens for patients with chronic hepatitis C.
Aliment Pharmacol Ther. 2024 Jul;60(2):276-277. doi: 10.1111/apt.18041. Epub 2024 Jun 16.
6
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
J Hepatol. 2019 Sep;71(3):498-504. doi: 10.1016/j.jhep.2019.05.021. Epub 2019 Jun 5.
7
[Two case reports of chronic hepatitis C retreatment].
Klin Mikrobiol Infekc Lek. 2020 Sep;26(3):96-98.
8
Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.
Can J Gastroenterol Hepatol. 2019 Mar 3;2019:4029541. doi: 10.1155/2019/4029541. eCollection 2019.
9
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
J Viral Hepat. 2021 Feb;28(2):302-316. doi: 10.1111/jvh.13430. Epub 2020 Nov 25.
10
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
J Viral Hepat. 2021 Sep;28(9):1256-1264. doi: 10.1111/jvh.13549. Epub 2021 Jun 8.
引用本文的文献
1
SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024.
Saudi J Gastroenterol. 2024 Jan 1;30(Supp 1):S1-S42. doi: 10.4103/sjg.sjg_333_23. Epub 2024 Jan 3.
本文引用的文献
1
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Clin Infect Dis. 2021 Nov 2;73(9):e3288-e3295. doi: 10.1093/cid/ciaa1318.
2
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
J Hepatol. 2019 Dec;71(6):1106-1115. doi: 10.1016/j.jhep.2019.07.020. Epub 2019 Aug 6.
3
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14.
4
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
J Viral Hepat. 2019 Aug;26(8):980-990. doi: 10.1111/jvh.13115. Epub 2019 May 10.
5
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.
6
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.
7
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
8
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.
9
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25.
10
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27.
Zotero 插件